Zacks Investment Research on MSN
NVO down 42% year to date: Is this an indication to sell the stock?
Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply ...
As Adam Fein of Drug Channels Institute puts it, these forces are finally puncturing the “ gross-to-net bubble ”—the vast gap ...
A proposed new federal law could provide some competitive guardrails for the company's most important product.
The price/sales TTM, EV/Sales TTM, and EV/EBITDA TTM of Novo, as compared to its peers, repeat substantially the same story ...
For 2026, the plan features significantly lower out-of-pocket costs for members who use the plan’s “narrow network” that ...
Novo Nordisk launched Ozempic in India on Friday—and the weight-loss drug will sell at a massive discount there, compared ...
In November, Seeking Alpha welcomed 24 new analysts. This article introduces them and showcases some of their top picks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback